Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB study shows benefits of Neupro against RLS

UCB study shows benefits of Neupro against RLS

18th April 2011

UCB has published data from a clinical study that demonstrates the effectiveness of the drug Neupro (rotigotine) against restless legs syndrome (RLS).

Results from the trial showed that use of UCB's drug was associated with a low risk of augmentation among RLS patients over the course of the placebo-controlled five-year study.

Augmentation involves the patient experiencing earlier, more intense and widespread symptoms and lower levels of relief from therapy, with the condition recognised as a complication of dopaminergic treatment.

This latest trial represents the longest prospective open-label RLS study conducted to date.

Dr Diego Garcia-Borreguero, lead investigator and director of the Sleep Research Institute in Madrid, said: "These study findings support rotigotine as a long-term treatment option and improve our understanding of the clinical relevance of augmentation and its progressive course in studies greater than one year."

Neupro was highlighted as one of the key drivers of UCB's strong 2010 financial results, with demand for the drug increasing in the last year.ADNFCR-8000103-ID-800503318-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.